Close Menu

NEW YORK (GenomeWeb) – Personalis announced today that it has signed a letter of intent to offer its next-generation tumor sequencing and interpretation technology in Canada through a collaboration with Toronto-based lab and research services firm Mount Sinai Services.

Under the terms of the deal, the two will create a framework to offer Personalis' Accuracy and Content Enhanced (ACE) technology for clinical diagnostic and research tumor molecular profile sequencing and analysis, as well as immuno-oncology sequencing clinical trials, to customers throughout Canada.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.

Sponsored by
Bionano Genomics

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Sponsored by

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.